HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

rivastigmine (Exelon)

Subscribe to New Research on rivastigmine

Also Known As:

Exelon; (S)-N-ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate; ENA 713; ENA-713; SDZ ENA 713; rivastigmine tartrate; Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)

Networked: 701 relevant articles (121 outcomes, 220 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Carboxylic Acids: 83
  - Acyclic Acids
    - Carbamates: 172
      - Phenylcarbamates: 6
        rivastigmine: 701

Experts

1.	Meng, Xiangyi: 26 articles (06/2015 - 01/2008)
2.	Lane, Roger: 20 articles (01/2010 - 01/2003)
3.	Farlow, Martin R: 17 articles (06/2015 - 09/2003)
4.	Grossberg, George T: 16 articles (07/2015 - 01/2002)
5.	Olin, Jason T: 14 articles (04/2011 - 06/2007)
6.	Tekin, Sibel: 12 articles (04/2011 - 12/2004)
7.	Koumaras, Barbara: 11 articles (04/2010 - 06/2003)
8.	Emre, Murat: 10 articles (01/2014 - 12/2004)
9.	Bullock, Roger: 10 articles (08/2010 - 03/2002)
10.	Cummings, Jeffrey L: 9 articles (01/2015 - 09/2005)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 04/01/2015 - "The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, open-label extension to the double-blind ACTION study. " 07/01/2009 - "A randomized controlled trial (n = 541) showed that, compared with placebo, rivastigmine (mean, 8.6 mg/d) significantly improved scores on 2 coprimary cognitive outcome scales in PDD, including the Alzheimer disease Cooperative Study-Clinician's Global Impression of Change. " 04/01/2008 - "This study shows that long-term treatment with rivastigmine, at dosages approved for therapeutic use in Alzheimer's disease, produces significant improvement in all behavioral symptoms in 2 forms of VaD, MID and sVaD, except delusions. " 01/01/2015 - "Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. " 03/01/2014 - "Because the cholinergic system is down-regulated in the brain of Alzheimer's disease patients, cognitive deficits in Alzheimer's disease patients are significantly improved by rivastigmine treatment. "
2.	Dementia (Dementias) 09/01/2006 - "The aim of the present study (a double-blind, placebo-controlled clinical trial) was to determine the utility of the Mattis dementia rating scale - the most commonly used scale in PD patients - to assess the efficacy of a 24-week rivastigmine treatment. " 09/01/2006 - "Compared with placebo, a 24-week rivastigmine treatment led to a significant improvement in the overall score on the Mattis dementia rating scale (p = 0.031), with a trend towards a significant improvement in the "Attention" subscale score (p = 0.061). " 01/01/2003 - "Preliminary data suggest that rivastigmine may provide significant benefits in patients with AD and cerebrovascular disease (mixed dementia), and in patients with VaD. " 07/01/2012 - "Our study suggests that there are differences in the efficacy of Ginkgo biloba and rivastigmine in the treatment of Alzheimer's dementia. " 12/16/2000 - "Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study."
3.	Parkinson Disease (Parkinson's Disease) 06/01/2015 - "Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study." 01/01/2013 - "The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen." 11/01/2001 - "This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. " 05/01/2015 - "Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson's Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory. " 01/01/2015 - "Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients."
4.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 05/01/2005 - "Small open-label studies of patients with subcortical vascular dementia showed that rivastigmine improved attention, executive function, apathy and other behavioral deficits. " 01/01/2013 - " trial included 40 participants with subcortical vascular dementia (age range 40 to 90 years) with a mean mini-mental state examination (MMSE) score of 13.0 and 13.4 in the rivastigmine and placebo arms, respectively. " 09/01/2008 - "VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. " 09/01/2008 - "Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study." 05/01/2005 - "Rivastigmine appears to be a promising agent in vascular dementia but its effects remain to be established in double-blind, placebo-controlled clinical trials."
5.	Schizophrenia (Dementia Praecox) 11/01/2003 - "In conclusion, rivastigmine significantly improved quality of life in subjects with schizophrenia. " 07/01/2012 - "Thirty inpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia treated with ECT were coadministered rivastigmine (3-4.5 mg/d) or placebo in a prospective, randomized, double-blind, placebo-controlled trial (maximum period of 4 weeks). " 07/01/2006 - "The current study investigated the cognitive effects of Rivastigmine given as an add-on therapy to antipsychotic-treated schizophrenia patients in a placebo-controlled double-blind design. " 07/01/2006 - "This study investigated the effect of rivastigmine on memory in schizophrenia using event-related potentials (ERPs). " 07/01/2006 - "Studies have reported beneficial effects of cholinergic enhancers, e.g., rivastigmine, on memory in schizophrenia but others have not. "

Related Drugs and Biologics

1.	donepezil (Aricept)
2.	Galantamine (Galanthamine)
3.	Cholinesterase Inhibitors (Anticholinesterases)
4.	Memantine (Namenda)
5.	Cholinesterases (Cholinesterase)
6.	rivastigmine (Exelon)
7.	Tacrine (Cognex)
8.	Trichlorfon (Metrifonate)
9.	Ginkgo biloba extract 761 (Rokan)
10.	Acetylcholinesterase

Related Therapies and Procedures

1.	Transdermal Patch
2.	Activities of Daily Living (ADL)
3.	Home Nursing (Nursing, Home)
4.	Cutaneous Administration
5.	Drug Therapy (Chemotherapy)